MarketPulse

futility analysis

11 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Immutep Faces Class Action Over $IMMP Trial Failure; Investors Have Days to Join Lawsuit

Immutep faces class action lawsuit alleging investor deception over TACTI-004 trial failure. Stock plunged 83% after March discontinuation announcement, despite positive January guidance. Lead plaintiff deadline: July 6, 2026.
IMMPclass action lawsuitmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Immutep Stock Collapses 82.6% After Failed Phase III Trial, Triggering Class Action

Immutep shares plummet 82.6% after discontinuing Phase III trial for eftilagimod alfa due to futility, triggering class action investigation by Rosen Law Firm.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Immutep Stock Plummets 82.6% After Failed Phase III Trial for Cancer Drug

Immutep stock crashed 82.6% after discontinuing a Phase III trial; Rosen Law Firm investigating potential securities fraud claims for shareholders.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··The Rosen Law Firm

Immutep Stock Collapses 82.6% After Failed Phase III Trial Halts Development

Immutep shares plummet 82.6% after independent committee halts Phase III trial for lead candidate eftilagimod alfa due to futility.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Immutep Stock Collapses 82.6% After Failed Cancer Trial, Triggering Class Action

Immutep's $IMMP shares plummeted after discontinuing Phase III trial for cancer drug. Rosen Law Firm investigates potential securities fraud claims.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··The Rosen Law Firm

Immutep Stock Plummets 82.6% After Failed Phase III Trial for Lead Cancer Drug

Immutep's stock crashed to $0.48 after its independent monitoring committee halted the TACTI-004 Phase III trial for eftilagimod alfa due to futility, prompting legal investigation.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Immutep Stock Crashes 82% After Failed Phase III Trial; Law Firm Launches Investor Investigation

Immutep stock collapsed 82% after Phase III trial failure. Law firm investigates potential securities fraud regarding disclosure timing and adequacy.
IMMPsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Rosen Law Firm

Immutep's Failed Trial Triggers Stock Collapse as Rosen Law Firm Launches Securities Investigation

Immutep's failed Phase III trial triggered an 82.6% stock collapse, prompting a securities investigation by The Rosen Law Firm into potential shareholder claims.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Immutep Stock Plummets 82.6% After Failed Phase III Trial; Class Action Lawsuit Looms

Immutep's stock crashed after discontinuing Phase III TACTI-004 trial for eftilagimod alfa due to futility, prompting securities litigation against the biotech firm.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Immutep Stock Plunges 82.6% After Failed Phase III Trial, Sparking Class Action

Immutep's $IMMP stock crashed after trial discontinuation announcement. Rosen Law Firm investigates securities claims for investor losses.
IMMPinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Immutep Stock Plummets 82.6% After Failed Phase III Trial, Sparking Lawsuit

Immutep's $IMMP stock crashed following discontinued Phase III trial for eftilagimod alfa. Rosen Law Firm launches investigation into potential securities claims and class action lawsuit.
IMMPinvestor lossessecurities class action